Open-Label Study of ARD-0403 in Testosterone Deficient Men (ARD-0403-010)
Primary Purpose
Hypogonadism
Status
Terminated
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
ARD-0403
Sponsored by
About this trial
This is an interventional treatment trial for Hypogonadism
Eligibility Criteria
Inclusion Criteria:
- Testosterone deficiency
- Completed study ARD-0403-004
Exclusion Criteria:
- Previous treatment with testosterone replacement therapy within 4 weeks
- Moderate-severe benign prostatic hypertrophy or prostatic cancer
- Haematocrit >50%
Sites / Locations
- Medical Affiliated Research Center, Inc
- Stanford University
- Harbor-UCLA Medical Center
- Northwestern University
- Johns Hopkins University
- Massachusetts General Hospital
- Duke University Medical Center
- Oregon Health and Science University
- Hospital of the University of Pennsylvania
- Baylor College of Medicine
- dgd Research
- VA Puget Sound Health Care System
Outcomes
Primary Outcome Measures
Efficacy
Secondary Outcome Measures
Safety and Tolerability
Full Information
NCT ID
NCT00562731
First Posted
November 21, 2007
Last Updated
March 28, 2008
Sponsor
Ardana Bioscience Ltd
1. Study Identification
Unique Protocol Identification Number
NCT00562731
Brief Title
Open-Label Study of ARD-0403 in Testosterone Deficient Men
Acronym
ARD-0403-010
Official Title
A Phase III, Open-Label Follow-on Study for Long-Term Safety and Efficacy of Testosterone Cream, in Testosterone Deficinet Men Completing Study ARD-0403-004
Study Type
Interventional
2. Study Status
Record Verification Date
March 2008
Overall Recruitment Status
Terminated
Why Stopped
Company strategic decision
Study Start Date
October 2007 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2008 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Ardana Bioscience Ltd
4. Oversight
5. Study Description
Brief Summary
Male hypogonadism, a disorder associated with testosterone deficiency, is frequently seen in clinical practice and has significant effects on patient well-being. The purpose of this study is to investigate the efficacy and safety of ARD-0403 as a testosterone replacement therapy in testosterone deficient men.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypogonadism
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
150 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
ARD-0403
Intervention Description
Daily transdermal ARD-0403
Primary Outcome Measure Information:
Title
Efficacy
Time Frame
Study Duration
Secondary Outcome Measure Information:
Title
Safety and Tolerability
Time Frame
Study Duration
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Testosterone deficiency
Completed study ARD-0403-004
Exclusion Criteria:
Previous treatment with testosterone replacement therapy within 4 weeks
Moderate-severe benign prostatic hypertrophy or prostatic cancer
Haematocrit >50%
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
R Swerdloff
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical Affiliated Research Center, Inc
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35801
Country
United States
Facility Name
Stanford University
City
Stanford
State/Province
California
ZIP/Postal Code
94305-5826
Country
United States
Facility Name
Harbor-UCLA Medical Center
City
Torrance
State/Province
California
ZIP/Postal Code
90502
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611-3008
Country
United States
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27706
Country
United States
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Baylor College of Medicine
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
dgd Research
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229-4801
Country
United States
Facility Name
VA Puget Sound Health Care System
City
Seattle
State/Province
Washington
ZIP/Postal Code
98493
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Open-Label Study of ARD-0403 in Testosterone Deficient Men
We'll reach out to this number within 24 hrs